Research & Development
Parnell launches first FDA-approved generic florfenicol and flunixin combination for bovine respiratory disease
1 April 2026 - Veterinary pharmaceutical company Parnell Technologies Pty Ltd on Wednesday announced the US launch of nixiFLOR, an injectable solution approved by the US Food and Drug Administration (...
Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC
1 April 2026 - Chinese biopharmaceutical company Abbisko Therapeutics Co Ltd (HKEX:02256) announced on Tuesday that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor i...
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
1 April 2026 - i-Lumen Scientific Inc, a developer of non-invasive, bioelectric stimulation therapy innovations in ophthalmology for the treatment of intermediate to advanced dry age-related macular d...
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
...
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
31 March 2026 - Danish pharmaceutical company ALK-Abelló A/S (ALK) (CPH:ALK-B) announced on Tuesday that the European Commission has granted marketing authorisation for EURneffy 1 mg, enabling ...
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
31 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Tuesday that the European Commission has granted conditional marketing authorisation for Rezurock (...